Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?

AbbVie is favored over Pfizer on its more visible growth outlook: Skyrizi and Rinvoq are projected to generate more than $31 billion of 2026 sales, growing over 20%, supporting approximately 10% total revenue growth and high-single-digit growth through 2029. Pfizer's 2026 consensus calls for sales and EPS declines of 0.2% and 7.5%, respectively, as COVID-product declines and a $1.1 billion 2026 patent-expiry impact weigh on results, despite 18%-22% growth from newer and acquired products. AbbVie shares are up 16.0% year-to-date versus Pfizer's 13.2%, while Pfizer remains cheaper at 9.56x forward earnings and offers a 6.1% dividend yield versus AbbVie's 1.9%.

Analysis

The relevant setup is not simply growth versus value: ABBV’s premium embeds durability of its immunology franchise just as payer leverage, oral competition and low-single-digit net-price erosion become more consequential. A deceleration in new-patient share for either core immunology asset would have an outsized multiple effect because that franchise funds pipeline dealmaking and offsets weaker discretionary aesthetics. JNJ is the most credible near-term share-taker in psoriasis, but the broader beneficiary of intensified immunology competition may be payers rather than another manufacturer, through tougher formulary rebates and lower realized net pricing across the class.

PFE’s low multiple and dividend create downside support, but they do not constitute a catalyst while earnings power bridges a multiyear gap to late-decade launches. The market should discount pre-approval obesity and PD-1/VEGF economics heavily: pivotal-study breadth raises execution cost and binary clinical/regulatory risk, while obesity commercialization will require differentiation against entrenched GLP-1 leaders. The more actionable near-term variable is whether acquired oncology assets can sustain growth above the rate of legacy-product erosion; quarterly oncology growth, launch uptake and net debt/FCF conversion matter more than long-range blockbuster targets.

Consensus favors ABBV’s visibility, while the contrarian opportunity is a relative-value mean reversion if ABBV’s estimate cuts persist and PFE delivers modest beats from cost actions and acquired-product sales. Over 1-3 months, prescription data and formulary positioning can move ABBV more than headline revenue growth; over 6-18 months, PFE needs evidence that its launch portfolio is becoming material enough to narrow the patent-cliff earnings trough. This thesis is falsified by ABBV maintaining immunology volume growth despite worsening rebates, or by PFE cutting medium-term cash-flow/dividend expectations or missing oncology-launch milestones.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral long PFE / short ABBV pair at equal dollar exposure; target 10-15% relative outperformance as PFE’s depressed multiple re-rates modestly and ABBV’s growth premium faces estimate risk. Exit if ABBV immunology prescription growth remains resilient through the next earnings print and PFE fails to show launch/oncology growth above legacy erosion.
• Do not add directional ABBV exposure ahead of the next quarterly prescription and gross-to-net update; retain only on evidence that immunology volume growth offsets pricing. A further 2-3% downgrade to forward EPS expectations would likely pressure a stock already valued above its historical earnings multiple.
• Use JNJ as a small 6-12 month immunology-competition hedge against ABBV rather than a standalone catalyst trade. Increase only if psoriasis formulary wins or early prescription-share data demonstrate material oral-drug substitution; the risk is that biologic persistence and broader indications limit switching.
• Keep PFE on a catalyst watch rather than buying long-dated obesity optionality now. Upgrade to a directional long only after quarterly evidence that acquired/new-product growth supports 2027 cash-flow estimates; missing data include product-level launch sales, clinical differentiation and post-acquisition leverage trajectory.